002693 Hainan Shuangcheng Pharmaceuticals
- 5.19
- -0.12-2.26%
Hainan Shuangcheng Pharmaceuticals News
Express News | Another Science and Technology Innovation Board IPO terminated
Workshop of Shuangcheng Pharma's Unit Passes Regulatory Inspection; Shares Up 3%
A production line of Ningbo Shuangcheng Pharmaceutical, a unit of Hainan Shuangcheng Pharmaceutical (SHE:002693), passed the good manufacturing practices or GMP inspection of the drug regulator in Chi
Express News | Shuangcheng Pharmaceutical: The holding subsidiary passed the GMP compliance inspection
Shuangcheng Pharmaceutical (002693.SZ): Ningbo Shuangcheng Oral Solids Workshop 1, capsule production line passed GMP compliance inspection
Gelonghui, May 21丨Shuangcheng Pharmaceutical (002693.SZ) announced that the company's holding subsidiary, Ningbo Shuangcheng Pharmaceutical Co., Ltd. (“Ningbo Shuangcheng”), learned from the Zhejiang Drug Administration website that Ningbo Shuangcheng Oral Solids Workshop 1. The capsule production line passed the GMP compliance inspection.
The CRO concept market began to weaken. Hongbo Pharmaceutical fell more than 9%, Azure Biotech fell more than 7%, and Canaan Technology, Shuangcheng Pharmaceutical, and Xintiandi followed suit.
The CRO concept market began to weaken. Hongbo Pharmaceutical fell more than 9%, Azure Biotech fell more than 7%, and Canaan Technology, Shuangcheng Pharmaceutical, and Xintiandi followed suit.
Shuangcheng Pharma Gets FDA Nod to Market Acromegaly Drug in US
Hainan Shuangcheng Pharmaceutical (SHE:002693) obtained marketing authorization from the US Food and Drug Administration for its octreotide acetate injection, according to a filing with the Shenzhen S
Express News | Shuangcheng Pharmaceutical: Octreotide acetate injection ANDA obtained marketing approval from the US FDA
Shuangcheng Pharmaceutical (002693.SZ): Net loss of 8.7427 million yuan in the first quarter
Gelonghui, April 29 | Shuangcheng Pharmaceutical (002693.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 42.7617 million yuan, a year-on-year decrease of 47.52%; net profit attributable to shareholders of listed companies - 8.7427 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 9.0527 million yuan; basic earnings per share - 0.0211 yuan.
The CRO concept was active at the beginning of the market. Baihua Pharmaceutical rose more than 8%, Boji Pharmaceutical rose 7%, and Shuangcheng Pharmaceutical, Haofan Biotech, and Yaben Chemical followed suit.
The CRO concept was active at the beginning of the market. Baihua Pharmaceutical rose more than 8%, Boji Pharmaceutical rose 7%, and Shuangcheng Pharmaceutical, Haofan Biotech, and Yaben Chemical followed suit.
Express News | Shuangcheng Pharmaceutical: The company passed the US FDA on-site inspection
Express News | Shuangcheng Pharmaceutical: The company obtained a drug registration certificate for injectable bortezomib
Hainan Shuangcheng Pharma's Unit Gets Green Light to Market Pregabalin Capsules
Ningbo Shuangcheng Pharmaceutical, a unit of Hainan Shuangcheng Pharmaceutical (SHE:002693), obtained approval from China's National Medical Products Administration to register pregabalin capsules for
Express News | Shuangcheng Pharmaceutical: Holding subsidiary Pregabalin capsules obtained drug registration certificate
Shuangcheng Pharmaceutical Gets Nod to Market Anticoagulant in Saudi Arabia
Hainan Shuangcheng Pharmaceutical (SHE:002693) said it can now market its bivalirudin for injection in Saudi Arabia after receiving approval from the country's drug regulator, the pharmaceutical compa
Express News | Shuangcheng Pharmaceutical: Bivalirudine for injection obtained Saudi Arabia's SFDA registration approval
Shuangcheng Pharmaceutical (002693.SZ): Changes in production license for holding subsidiary Ningbo Shuangcheng Pharmaceutical
Gelonghui, March 7, 丨 Shuangcheng Pharmaceutical (002693.SZ) announced that the company's holding subsidiary, Ningbo Shuangcheng Pharmaceutical Co., Ltd. (“Ningbo Shuangcheng”), recently obtained a “Pharmaceutical Production License” issued by the Zhejiang Drug Administration. This change mainly involves extending the contract production validity period of the contract company SC-C134 to November 13, 2027.
Pharmacovigilance is raging! The CRO sector has exploded. What do you think of the future market? Focus on 3 key events
CITIC Securities believes that short-term fluctuations in overseas policies do not affect the long-term fundamental logic of Chinese pharmaceutical outsourcing companies.
Shuangcheng Pharmaceutical (002693.SZ): Pharmaceutical production license change
Gelonghui, Feb. 6: Shuangcheng Pharmaceutical (002693.SZ) announced that the company recently obtained the revised “Pharmaceutical Production License” issued by the Hainan Drug Administration. The main matters involved in this change are: it was agreed that the company would increase the production scope at No. 16 Xingguo Road, Xiuying District, Haikou City: C144 (Second API Workshop, C144 Production Line for Polypeptide APIs), limited to registration and use; other details remained unchanged.
Shuangcheng Pharmaceutical (002693.SZ): Multiple peptide varieties (including APIs and formulations) have been approved and marketed in developed countries
Gelonghui January 31 丨 An investor asked Shuangcheng Pharmaceutical (002693.SZ) on the investor interactive platform, “Does the company have professional peptide formulation research and development capabilities? Or is it just OEM? “It does not have R&D capabilities,” the company replied that the company focuses on R&D, production and sales of peptide products. Multiple peptide varieties (including APIs and formulations) have been approved and marketed in developed countries, and the production site has also passed GMP inspections by the US FDA and the European Union. The company has rich experience in R&D, registration, production and marketing of chemically synthesized peptide drugs, and has successfully developed multiple chemical syntheses
Shuangcheng Pharmaceutical (002693.SZ): No cosmetics business
Gelonghui, January 29丨An investor asked Shuangcheng Pharmaceutical (002693.SZ) on the investor interactive platform, “Does the company have a cosmetics business?” The company replied that the company has no cosmetics business.
Analysis
Price Target
No Data
